These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 12168865)
1. Combination of HCGbeta, CA 19-9 and CEA with logistic regression improves accuracy in gastrointestinal malignancies. Louhimo J; Finne P; Alfthan H; Stenman UH; Haglund C Anticancer Res; 2002; 22(3):1759-64. PubMed ID: 12168865 [TBL] [Abstract][Full Text] [Related]
2. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919 [TBL] [Abstract][Full Text] [Related]
3. Estimating the probability of cancer with several tumor markers in patients with colorectal disease. Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C Oncology; 2004; 66(4):296-302. PubMed ID: 15218297 [TBL] [Abstract][Full Text] [Related]
4. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733 [TBL] [Abstract][Full Text] [Related]
5. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer. Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C Tumour Biol; 2004; 25(5-6):228-34. PubMed ID: 15627885 [TBL] [Abstract][Full Text] [Related]
6. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19-9 and CA 72-4 in gastric cancer. Fernández-Fernández L; Tejero E; Tieso A; Rabadán L; Munoz M; Santos I Int Surg; 1996; 81(4):400-2. PubMed ID: 9127805 [TBL] [Abstract][Full Text] [Related]
7. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer. Flamini E; Mercatali L; Nanni O; Calistri D; Nunziatini R; Zoli W; Rosetti P; Gardini N; Lattuneddu A; Verdecchia GM; Amadori D Clin Cancer Res; 2006 Dec; 12(23):6985-8. PubMed ID: 17145818 [TBL] [Abstract][Full Text] [Related]
8. Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Louhimo J; Alfthan H; Stenman UH; Haglund C Oncology; 2004; 66(2):126-31. PubMed ID: 15138364 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798 [TBL] [Abstract][Full Text] [Related]
10. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions. Gaspar MJ; De Miguel J; García Díaz JD; Díez M Anticancer Res; 2008; 28(5B):2947-52. PubMed ID: 19031938 [TBL] [Abstract][Full Text] [Related]
11. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma. Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617 [TBL] [Abstract][Full Text] [Related]
12. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Schneider J; Schulze G Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971 [TBL] [Abstract][Full Text] [Related]
13. [Comparative study of the role of CA 19-9, CA 72-4 and CEA tumor antigens in the diagnosis of pancreatic cancer and other gastrointestinal malignant diseases]. Czakó L; Takács T; Babarczy E; Dux L; Lonovics J Orv Hetil; 1997 Nov; 138(47):2981-5. PubMed ID: 9432648 [TBL] [Abstract][Full Text] [Related]
14. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer]. Clavé P; Boadas J; González-Carro P; Mora J; Pérez C; Martínez A; Roca M; Lluís F; Farré A Gastroenterol Hepatol; 1999; 22(7):335-41. PubMed ID: 10535205 [TBL] [Abstract][Full Text] [Related]
15. Application of C12 multi-tumor marker protein chip in the diagnosis of gastrointestinal cancer: results of 329 surgical patients and suggestions for improvement. Yang XQ; Yan L; Chen C; Hou JX; Li Y Hepatogastroenterology; 2009; 56(94-95):1388-94. PubMed ID: 19950797 [TBL] [Abstract][Full Text] [Related]
16. Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix. Carmignani CP; Hampton R; Sugarbaker CE; Chang D; Sugarbaker PH J Surg Oncol; 2004 Sep; 87(4):162-6. PubMed ID: 15334630 [TBL] [Abstract][Full Text] [Related]
17. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture. Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of serum tumor markers in asymptomatic individuals. Eleftheriadis N; Papaloukas C; Pistevou-Gompaki K J BUON; 2009; 14(4):707-10. PubMed ID: 20148467 [TBL] [Abstract][Full Text] [Related]
19. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. Nazli O; Bozdag AD; Tansug T; Kir R; Kaymak E Hepatogastroenterology; 2000; 47(36):1750-2. PubMed ID: 11149048 [TBL] [Abstract][Full Text] [Related]
20. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700. van Dalen A; Kessler AC Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]